Lv1
30 积分 2023-06-25 加入
Real-world(RW)use patterns,effectiveness,and tolerability of sacituzumab govitecan(SG)for second-line(2L)and later treatment of metastatic triple-negative breast cancer(mTNBC)
1天前
求助中
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer
14天前
已完结
A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study
15天前
已完结
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022. Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022
15天前
已完结
Primary prophylaxis of febrile neutropenia using long-acting granulocyte colony-stimulating factors in female patients receiving dose-dense biweekly chemotherapy in the clinical routine
25天前
已关闭
中国临床肿瘤学会(CSCO)肿瘤放化疗相关中性粒细胞减少症规范化管理指南(2021)
27天前
已完结
Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options
28天前
已完结
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer
28天前
已完结
Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas
29天前
已完结
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
30天前
已完结
皖公网安备34019202002308
